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Reproductive phase transition mood disorder 
HPO-axis 
A B S T R A C T   
Women’s increased risk for depression during reproductive transitions suggests an involvement of the 
hypothalamic-pituitary-ovarian (HPO) axis. This is the first systematic review and meta-analysis of HPO func-
tioning in female mood disorders. Inclusionary criteria were: i) women suffering from premenstrual dysphoric 
disorder (PMDD) or a depressive disorder, ii) assessment of HPO-axis related biomarkers, iii) a case-control 
design. Sixty-three studies (N = 5,129) were included. There was evidence for PMDD to be paralleled by 
lower luteal oestradiol levels. Women with depression unrelated to reproductive transition showed lower 
testosterone levels than healthy controls and there was some evidence for lower dehydroepiandrosterone sulfate 
levels. There were no differences in HPO-related parameters between women with pregnancy, postpartum, and 
perimenopausal depression and controls. Women with PMDD and depression unrelated to reproductive transi-
tions exhibit specific changes in the HPO-axis, which potentially contribute to their symptoms. Further research 
into reproductive mood disorders characterised by extreme endocrine changes is warranted.   
1. Introduction 
It has long been known that women have a twofold increased lifetime 
risk of suffering from depressive disorders compared to men (Kessler and 
Bromet, 2013). Although psychosocial factors clearly contribute to this, 
accumulating evidence also suggests hormonal influences. 
Given that menarche is linked to an elevated risk for a first-onset 
depressive disorder (Soares and Zitek, 2008), a likely involved system 
is the hypothalamic-pituitary-ovarian (HPO) axis. Among other func-
tions, follicle-stimulating hormone (FSH) and luteinising hormone (LH) 
act at the ovaries to stimulate the production of steroid hormones, such 
as oestradiol and progesterone (Burger et al., 2004). These steroid 
hormones are potent neuromodulators affecting brain regions involved 
in mood and behaviour (Toren et al., 1996). Similarly, allopregnanolone 
(ALLO), testosterone, and dehydroepiandrosterone (DHEA) have been 
implicated in mood and cognition (Toren et al., 1996; Bäckström et al., 
2014; Pluchino et al., 2015). In human pregnancy, particularly, a pro-
gressive increase in placental production of corticotropin-releasing 
hormone (CRH), adenocorticotropic hormone (ACTH), estrogens and 
progesterone are observed, followed by an abrupt drop at delivery and 
reaching pregravid levels in the initial postpartum days (Economides 
et al., 1987; Speroff and Fritz, 2005). In line with these findings, hor-
monal alterations during the luteal phase (De Ronchi et al., 2005), 
pregnancy and postpartum period (Brummelte and Galea, 2010), and 
perimenopause (Schmidt and Rubinow, 2009) have been shown to be 
involved in the pathogenesis of female depressive disorders. 
Indeed, various reproductive transition phase mood disorders have 
been described in the literature. Premenstrual dysphoric disorder 
(PMDD) is characterised by a variety of affective and somatic changes 
occurring during the luteal phase of the menstrual cycle; pregnancy and 
postpartum depressive disorders (PPD) present core symptoms compa-
rable to major depression, with a distinctive onset around childbirth; 
perimenopausal depressive disorder involves mood symptoms and other 
complaints prevailing during the menopausal transition (Studd and 
Nappi, 2012). Notably, however, (major) depressive disorders, which 
are among the most prevalent and debilitating mental disorders, can 
occur throughout the lifespan and are not necessarily tied to reproduc-
tive events (Kennedy and Eisfeld, 1999). 
In order to investigate to what extent the HPO axis is involved in 
various female mood disorders, we conducted the first systematic review 
and meta-analysis comparing women with and without reproductive 
transition phase mood disorders as well as women with and without 
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depressive disorders unrelated to reproductive transition phases 
regarding HPO-axis-related parameters. 
2. Methods 
2.1. Search 
Records were initially identified as part of a larger PubMed and 
PsycInfo search from the first available year until November 2018 
(Fischer et al., 2019). This search was repeated to include all papers until 
September 2020. Key words and subject headings were chosen in 
accordance with the thesaurus of each database. A two-component 
search string was used: 1) “depressive disorder”, including synonyms 
and 2) “HPO axis”, including synonyms and components (e.g., “oestra-
diol”; see Table 1). A human filter was applied and only studies pub-
lished in English, German, Dutch, French, Italian, Portuguese or Spanish 
were considered. A manual review of reference lists was conducted to 
identify additional studies. We sought for summary estimate data. 
2.2. Screening 
The following inclusion criteria were used: 1) adult women suffering 
from PMDD according to the Diagnostic and Statistical Manual of Mental 
Disorders (DSM) (APA, 2013) or any depressive disorder according to 
the DSM, the International Classification of Diseases (ICD) (WHO, 
1992), Research Diagnostic Criteria (RDC) (Spitzer et al., 1978), or, for 
depression in pregnancy and PPD, the use of the Edinburgh Postnatal 
Depression Scale (Cox et al., 1996) including validated cut-off scores for 
the country where the study was conducted, 2) assessment of FSH, LH, 
oestradiol, progesterone, allopregnanolone, testosterone, DHEA, or 
DHEA sulfate (DHEA-S) or related genes, and 3) a case-control design. 
Studies on bipolar disorder were excluded unless results were reported 
separately for unipolar and bipolar depression; the same applied to 
studies including men. Studies in which hormonal medications were 
allowed were excluded, unless results for an unmedicated group were 
reported. Besides pregnancy and early postpartum studies, if hormone 
intake was not mentioned as an exclusion criterion, studies were 
excluded. Studies accepting use of antidepressants without separately 
reporting results for unmedicated patients were excluded. Comorbidity 
as well as intake of medication other than hormones or psychotropic 
drugs were allowed, but recorded for subgroup analyses/meta-re-
gressions. The screening was conducted by two of the study investigators 
(RAC and SF) and disagreements were discussed until consensus was 
reached. 
2.3. Data extraction 
For each study, information about the sample size, ethnicity, diag-
nostic procedures, eligibility criteria, HPO-axis assessment, and relevant 
results were collected. Risk of bias was evaluated using a quality 
assessment scale adapted from previous meta-analyses (Fischer et al., 
2019; Tak et al., 2011) (see Supplement Tables 1–4). Five items were 
scored on a 3-point scale (0–2). Data extraction was conducted by two of 
the study investigators (RAC and SF) and the risk of bias was assessed by 
two of the study investigators (UE and SF) and a research assistant. 
2.4. Data analysis 
Standardised mean differences (SMD) were calculated based on 
means or medians and standard deviations, standard errors, or ranges. 
Whenever insufficient information was reported, the study authors were 
contacted. Studies whose authors were unable to provide the necessary 
statistical data were included in the systematic review. Hedges’ g was 
calculated to correct for small sample bias and studies were weighed and 
integrated based on their inverse variance (Borenstein et al., 2009). 
Random-effects meta-analyses were computed using Review Manager 
Table 1 
Search Terms.  
PubMed PsycINFO 






















Estrogens as MeSH Estrogens as DE 
Follicle Stimulating Hormone as MeSH Follicle Stimulating Hormone as DE 
“follicle-stimulating hormone” “follicle-stimulating hormone” 
FSH FSH 
gestagen* gestagen* 
Gestagen as MeSH  
“gonadal hormone” “gonadal hormone” 
“gonadal hormones” “gonadal hormones” 
“gonadal steroid” “gonadal steroid” 
“gonadal steroid hormones”  
“gonadal steroids” “gonadal steroids” 
“gonadal axis” “gonadal axis” 
gonadotropin* Gonadotrophic Hormones as DE 
Gonadotropins as MeSH gonadotropin* 
GPER GPER 
GPR30 GPR30 
“hypothalamic-pituitary-gonadal axis” “hypothalamic-pituitary-gonadal axis” 
“hypothalamic-pituitary-ovarian axis” “hypothalamic-pituitary-ovarian axis” 
LH LH 
Luteinizing Hormone as MeSH Luteinizing Hormone as DE 
“luteinising hormone” “luteinising hormone” 












Progesterone as MeSH Progesterone as DE 
P4 P4 
“sex hormone” “sex hormone” 
“sex hormones” “sex hormones” 
“sex steroid” “sex steroid” 
“sex steroids” “sex steroids” 
SHBG SHBG 
testosterone testosterone  
Depressive disorders Depressive disorders 
“affective disorder” “affective disorder” 
“affective disorders” “affective disorders” 





“mood disorder” “mood disorder” 
Mood Disorders as MeSH “mood disorders” 
(continued on next page) 
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(RevMan) Version 5.3 (Higgins and Green, 2011). Forest plots were also 
created with RevMan. Separate analyses were conducted for each HPO- 
axis parameter and, for PMDD, for each menstrual cycle phase. Het-
erogeneity was estimated using I2 and X2 statistics. Subgroup analyses 
and random-effects meta-regressions were undertaken to study potential 
effect modifiers (https://mason.gmu.edu/~dwilsonb/ma.html). This 
included all subitems of the quality assessment scales, sampling tissue 
(blood vs. saliva), as well as menstrual cycle phase (for PMDD) and 
menopausal status (for depressive disorders unrelated to reproductive 
transition phases). When menopausal status was not appropriately 
described, we inferred it based on the participants’ mean age. Funnel 
plots, Egger’s regression test and a trim-and-fill procedure were used to 
examine publication bias if more than ten studies were available. 
3. Results 
3.1. General study characteristics 
The study selection is summarised in Fig. 1 and the study charac-
teristics are presented in Tables 2–5. Sixty-three studies were included 
(PMDD = 33, pregnancy and PPD = 8, perimenopausal depressive dis-
order = 5, depressive disorders unrelated to reproductive transition 
phases = 17), comprising N = 5,129 women. The studies were published 
between 1981 and 2019. Sample sizes varied from 10 to 713. Age ranged 
from 18 to 85 years. Regarding HPO-axis assessments, 44.5% of the 
included studies measured parameters in serum, 28.7% used plasma, 
7.9% blood (not further specified), 4.8% saliva, 3.1% urine, and 7.9% 
both serum and plasma, while 3.1% did not reveal information on tissue. 
3.2. Premenstrual dysphoric disorder 
Thirty-three studies compared women with PMDD and healthy 
controls regarding HPO-related parameters. Four of these were likely to 




“postpartum blues” “postpartum blues” 
“premenstrual dysphoric disorder” “premenstrual dysphoric disorder” 
Premenstrual Dysphoric Disorder as MeSH Premenstrual Dysphoric Disorder as DE 
“premenstrual syndrome” “premenstrual syndrome” 
Premenstrual Syndrome as MeSH Premenstrual Syndrome as DE 
“premenstrual symptoms” “premenstrual symptoms”  
Fig. 1. Study selection.  
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Table 2 
Characteristics of studies investigating hormones of the hypothalamic-pituitary-ovarian axis in premenstrual dysphoric disorder.  
Study N (total) Cases Controls Measurement time points Tissue Hormones Quality rating 












Cerin et al., 1993 N = 47 n = 27 n = 20 Follicular and luteal phase Serum Oestradiol 
Progesterone 
6 
Dennerstein et al., 1993 N = 83 n = 65 n = 18 Follicular phase, ovulation, luteal phase Urine Oestrogen 4 








Rapkin et al., 1997 N = 71 n = 35 n = 36 Luteal phase Serum Progesterone 
Allopregnanolone 
6 
Bloch et al., 1998 N = 20 n = 10 n = 10 Follicular phase, ovulation, luteal phase Plasma Testosterone 5 
Rapkin et al., 1998 N = 64 n = 32 n = 32 Luteal phase Serum Oestradiol 
Progesterone 
6 
Sundström et al., 1998 N = 24 n = 12 n = 12 Follicular and luteal phase Plasma Oestradiol 
Progesterone 
4 
Sundström et al., 1999 N = 14 n = 7 n = 7 Follicular and luteal phase Plasma Oestradiol 
Progesterone 
2 





Girdler et al., 2001 N = 36 n = 24 n = 12 Follicular and luteal phase Plasma/serum Progesterone 
Allopregnanolone 
7 









Klatzkin et al., 2006 N = 52 n = 23 n = 29 Luteal phase Plasma/serum Progesterone 
Allopregnanolone 
6 




Kask et al., 2009 N = 28 n = 16 n = 12 Luteal phase Plasma Oestradiol 
Progesterone 
1 
Rapkin et al., 2011 N = 24 n = 12 n = 12 Follicular and luteal phase Plasma Oestradiol 
Progesterone 
5 
Gingnell et al., 2012 N = 29 n = 14 n = 15 Follicular and luteal phase Serum Oestradiol 
Progesterone 
2 
Shechter et al., 2012 N = 10 n = 5 n = 5 Follicular and luteal phase Plasma Oestradiol 
Progesterone 
3 
Akturk et al., 2013 N = 38 n = 20 n = 18 Follicular and luteal phase Serum Progesterone 5 
Gingnell et al., 2013 N = 28 n = 14 n = 14 Follicular and luteal phase Serum Oestradiol 
Progesterone 
3 
(Segebladh et al., 2013) N = 56 n = 26 n = 30 Luteal phase Serum Allopregnanolone 5 
Ko et al., 2014 N = 142 n = 67 n = 75 Follicular and luteal phase Serum Oestrogen 
Progesterone 
4 




Oral et al., 2015 N = 49 n = 20 n = 29 Follicular and luteal phase Serum Oestradiol 
Progesterone 
7 
(Eriksson et al., 2016) N = 20 n = 12 n = 8 Follicular and luteal phase Plasma Oestradiol 
Progesterone 
4 
Timby et al., 2016 N = 20 n = 10 n = 10 Follicular and luteal phase Serum Allopregnanolone 5 
Ozcan et al., 2017 N = 50 n = 20 n = 30 Follicular and luteal phase Serum Oestrogen 
Progesterone 
6 
Yen et al., 2018 N = 196 n = 100 n = 96 Follicular and luteal phase Serum Oestrogen 4 
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have some participant overlap (Gingnell et al., 2013, 2012; Rapkin et al., 
1997, 1998). For the hormonal studies, the average score of the quality 
assessments was 4.7 (see Table 2). 
3.2.1. Genetic studies 
One study investigated SNPs within oestrogen receptor genes (ESR1, 
ESR2). The authors found the genotype and allele frequencies of four 
SNPs (rs3020314, rs3003917, rs3020377, rs1884051) within ESR1 to 
significantly differ between Caucasian women with PMDD and controls 
(Burger et al., 2004). No significant differences emerged regarding 
ESR2. 
3.2.2. Hormonal studies 
3.2.2.1. Follicle-stimulating hormone. Three studies assessed FSH in the 
follicular phase, whereas four assessed it in the luteal phase (Jovanovic 
et al., 2006; Rubinow et al., 1988; Parry et al., 2000; Yen et al., 2019). 
Insufficient data were available for a meta-analysis in the follicular 
phase, but meta-analysis in the luteal phase exhibited a null-finding (k =
2; g = 0.07, 95 %CI [−0.28, 0.42]; Z = 0.39, p = .70; I2 = 0%). 
3.2.2.2. Luteinising hormone. Four studies measured LH in the follicular 
phase (Jovanovic et al., 2006; Rubinow et al., 1988; Parry et al., 2000; 
Wang et al., 1996). Meta-analysis revealed no differences between cases 
and controls (k = 2; g = 0.17, 95 %CI [−0.72, 1.06]; Z = 0.38, p = .70). 
Seven studies measured LH in the luteal phase; again, meta-analysis 
revealed a null-finding (k = 4; g = −0.12, 95 %CI [−0.36, 0.13]; Z =
0.93, p = .35; I2 = 0%) (Jovanovic et al., 2006; Rubinow et al., 1988; 
Parry et al., 2000; Yen et al., 2019; Wang et al., 1996; Thys-Jacobs et al., 
2008; Rapkin et al., 1996). 
3.2.2.3. Oestradiol. Nineteen studies measured oestradiol in the follic-
ular phase (Gingnell et al., 2013, 2012; Jovanovic et al., 2006; Rubinow 
et al., 1988; Parry et al., 2000; Wang et al., 1996; Rapkin et al., 2011; 
Shechter et al., 2012; Ko et al., 2014; Bartley et al., 2015; Oral et al., 
2015; Ozcan et al., 2017; Eriksson et al., 2016; Roca et al., 2003; 
Sundström et al., 1998, 1999; Dennerstein et al., 1993; Cerin et al., 
1993; Yen et al., 2018). Meta-analysis yielded no group differences (k =
16; g = −0.08, 95 %CI [−0.25, 0.10]; Z = 0.87, p = .39; I2 = 15%; χ2 =
17.68, df = 15, p = .28; see also Fig. 2). Three studies assessed oestradiol 
in the ovulation phase (Thys-Jacobs et al., 2008; Bartley et al., 2015; 
Dennerstein et al., 1993) and meta-analysis yielded a non-significant 
result (k = 3; g = −0.11, 95 %CI [−0.67, 0.45]; Z = 0.37, p = .71; I2 
= 70%). Twenty-four studies measured oestradiol in the luteal phase 
(Gingnell et al., 2013, 2012; Rapkin et al., 1998; Jovanovic et al., 2006; 
Rubinow et al., 1988; Parry et al., 2000; Yen et al., 2019; Wang et al., 
1996; Thys-Jacobs et al., 2008; Rapkin et al., 2011; Shechter et al., 2012; 
Notes: DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulphate, FSH = follicle-stimulating hormone, LH = luteinising hormone, NI = not 
indicated. 
Table 3 
Characteristics of studies investigating hormones of the hypothalamic-pituitary-ovarian axis in pregnancy and postpartum depressive disorder.  
Study N 
(total) 
Cases Controls Measurement time points Tissue Hormones Quality 
rating 
Harris et al., 1989 N = 147 n = 32 n = 115 6–8 weeks postpartum Plasma Oestradiol 
Progesterone 
2 
Harris et al., 1996 N = 120 N = 7 N = 113 At baseline, and 1, 5 and 35 days postpartum Plasma Oestradiol 
Progesterone 
2 





Chatzicharalampous et al., 
2011 






Posadas et al., 2012 N = 33 n = 11 n = 22 At approximately 30 weeks gestation Serum Oestradiol 
Progesterone 
7 
Saleh et al., 2013 N = 120 n = 60 n = 60 7 days postpartum Serum Oestradiol 4 
Note: NI = not indicated. 
Table 4 
Characteristics of studies investigating hormones of the hypothalamic-pituitary-ovarian axis in perimenopausal depressive disorder.  
Study N 
(total) 
Cases Controls Measurement time points Tissue Hormones Quality 
rating 
Schmidt et al., 2002 N = 92 n = 47 N = 45 At least six months of irregular menstrual cycles, but no more than 12 








Flores-Ramos et al., 
2014 





Karaoulanis et al., 
2014 




Gordon et al., 2016 N = 19 n = 9 n = 10 Perimenopause according to STRAW criteria Saliva Oestradiol 4 
Hui et al., 2016 N = 64 n = 38 n = 26 Perimenopause according to STRAW criteria Serum Oestradiol 
Testosterone 
5 
Note: DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulphate, FSH = follicle-stimulating hormone, LH = luteinising hormone, STRAW =
Stages of Reproductive Aging Workshop. 
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Ko et al., 2014; Bartley et al., 2015; Oral et al., 2015; Ozcan et al., 2017; 
Eriksson et al., 2016; Roca et al., 2003; Sundström et al., 1998, 1999; 
Dennerstein et al., 1993; Cerin et al., 1993; Yen et al., 2018; Kask et al., 
2009; Rapkin et al., 1996). While meta-analysis was non-significant (k =
21; g = −0.09, 95 %CI [−0.29, 0.11]; Z = 0.90, p = .37; see also Fig. 3), 
heterogeneity was significant (I2 = 51%; χ2 = 41.20, df = 20, p = .004). 
A subgroup analysis of late luteal phase studies did not alter the null- 
finding. However, meta-regression revealed that studies standardising 
their hormonal measures regarding time of day found lower oestradiol 
in individuals with PMDD than in healthy controls (β =−0.37, p = .044; 
k = 7; g = −0.35, 95 %CI [−0.57, −0.13]; Z = 3.12, p = .002; I2 = 0%). 
3.2.2.4. Progesterone. Twenty-one studies measured progesterone in 
the follicular phase (Gingnell et al., 2013, 2012; Jovanovic et al., 2006; 
Rubinow et al., 1988; Parry et al., 2000; Wang et al., 1996; Thys-Jacobs 
et al., 2008; Rapkin et al., 2011; Shechter et al., 2012; Ko et al., 2014; 
Bartley et al., 2015; Oral et al., 2015; Ozcan et al., 2017; Eriksson et al., 
2016; Roca et al., 2003; Sundström et al., 1998, 1999; Cerin et al., 1993; 
Yen et al., 2018; Akturk et al., 2013; Eriksson et al., 1992). No significant 
differences emerged between cases and controls (k = 16; g = −0.19, 95 
%CI [−0.42, 0.03]; Z = 1.68, p = .09; I2 = 32%; χ2 = 21.98, df = 15, p =
.11; see also Fig. 4). Three studies measured progesterone in the 
ovulation phase. Meta-analysis yielded a null-finding (k = 2; g = 0.08; 
Table 5 
Characteristics of studies investigating hormones of the hypothalamic-pituitary-ovarian axis in depressive disorder unrelated to reproductive transition phases.  
Study N (total) Cases Controls Measurement time points Tissue Hormones Quality rating 



























Rajewska and Rybakowski, 2003 N = 90 n = 60 n = 30 Premenopause, follicular phase Blood FSH 
Oestradiol 
2 





Poór et al., 2004 N = 32 n = 11 n = 21 NI Urine DHEA 2 





Oulis et al., 2014 N = 103 n = 38 n = 65 Premenopause and postmenopause Plasma Testosterone 
DHEA-S 
4 
(Kumsar et al., 2014) N = 82 n = 52 n = 30 Premenopause, follicular phase Serum Testosterone 6 
Findikli et al., 2017 N = 58 n = 34 n = 24 Premenopause Serum Oestradiol 3 
Jiang et al., 2017 N = 37 n = 18 n = 19 Premenopause, follicular phase Saliva DHEA 
DHEA-S 
8 
Özdemir et al., 2017 N = 107 n = 58 n = 49 NI Serum Testosterone 3 
Note: DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulfate, FSH = follicle-stimulating hormone, LH = luteinising hormone. 
Fig. 2. Forest plot of studies comparing oestradiol in the follicular phase between women with premenstrual dysphoric disorder (PMDD) and healthy controls; 
negative effect sizes indicate that women with PMDD had lower oestradiol levels than controls. 
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95 %CI [−0.70, 0.86]; Z = 0.21, p = .83; I2 = 38%). In the luteal phase, 
27 studies were included (Gingnell et al., 2013, 2012; Rapkin et al., 
1997, 1998; Jovanovic et al., 2006; Rubinow et al., 1988; Parry et al., 
2000; Yen et al., 2019; Wang et al., 1996; Thys-Jacobs et al., 2008; 
Rapkin et al., 2011; Shechter et al., 2012; Ko et al., 2014; Bartley et al., 
2015; Oral et al., 2015; Ozcan et al., 2017; Eriksson et al., 2016; Roca 
et al., 2003; Sundström et al., 1998, 1999; Cerin et al., 1993; Kask et al., 
2009; Rapkin et al., 1996; Akturk et al., 2013; Eriksson et al., 1992; 
Klatzkin et al., 2006; Girdler et al., 2001). Progesterone did not differ 
between the two groups in the meta-analysis (k = 22; g = −0.07, 95 %CI 
[−0.26, 0.11]; Z = 0.79, p = .43; see also Fig. 5), but heterogeneity was 
significant (I2 = 40%; χ2 = 34.97, df = 21, p = .03). A subgroup analysis 
of late luteal phase studies did not change the finding, and meta- 
regression identified no effect modifiers. 
3.2.2.5. Allopregnanolone. Two studies compared ALLO in the follicular 
phase (Klatzkin et al., 2006; Timby et al., 2016). Meta-analysis suggested 
higher ALLO in women with PMDD compared to controls (k = 2, g =
0.97; 95 %CI [0.47, 1.46]; Z = 3.84, p = .0001; I2 = 0%). In the luteal 
phase, four studies were included. Meta-analysis found no group dif-
ferences (k = 2; g = 0.35, 95 %CI [−0.11, 0.81]; Z = 1.49, p = .14; I2 =
1%). 
3.2.2.6. Testosterone. Five studies measured testosterone in the follic-
ular phase (Rubinow et al., 1988; Bartley et al., 2015; Roca et al., 2003; 
Eriksson et al., 1992; Bloch et al., 1998). Meta-analysis yielded an 
overall g of −0.44 (k = 4; 95 %CI [−0.90, 0.03]; Z = 1.85, p = .06; I2 =
8%; χ2 = 3.27, df = 3; p = .35). Three studies examined testosterone in 
the ovulatory phase (Bartley et al., 2015; Eriksson et al., 1992; Bloch 
et al., 1998). Meta-analysis demonstrated comparable testosterone 
concentrations between groups (k = 3; g =−0.80, 95 %CI [−1.63, 0.02]; 
Z = 1.91, p = .06; I2 = 63%). Five studies examined testosterone in the 
Fig. 3. Forest plot of studies comparing oestradiol in the luteal phase between women with premenstrual dysphoric disorder (PMDD) and healthy controls; negative 
effect sizes indicate that women with PMDD had lower oestradiol levels than controls. 
Fig. 4. Forest plot of studies comparing progesterone in the follicular phase between women with premenstrual dysphoric disorder (PMDD) and healthy controls; 
negative effect sizes indicate that women with PMDD had lower progesterone levels than controls. 
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luteal phase (Rubinow et al., 1988; Bartley et al., 2015; Roca et al., 2003; 
Eriksson et al., 1992; Bloch et al., 1998). Meta-analysis showed a null- 
finding (k = 4; g = −0.20, 95 %CI [−0.91, 0.51]; Z = 0.54, p = .59; 
I2 = 60%; χ2 = 7.50, df = 3; p = .06). 
3.3. Pregnancy and postpartum depressive disorder 
Eight studies compared HPO parameters between women with vs. 
without a depressive disorder during pregnancy or PPD. For the hor-
monal studies, the quality score was 4 (see Table 3). 
3.3.1. Genetic studies 
Two genetic studies compared polymorphisms within ESR1 and 
ESR2 (Pinsonneault et al., 2013; Tan et al., 2018). Pinsonneault et al. 
(2013) detected that two out of nine investigated polymorphisms within 
ESR1 (rs2077647 and TA repeat) were significantly more frequent in 
women with PPD as compared to healthy controls, but this result did not 
withstand correction for multiple testing (Pinsonneault et al., 2013). 
Likewise, Tan and colleagues (2018) found that five polymorphisms 
within ESR1 and ESR2 (ESR1: rs2077647, rs2234693, rs9340799, TA 
repeat; ESR2: rs4986938) did not distinguish Chinese women with PPD 
from healthy controls (Tan et al., 2018). 
3.3.2. Hormonal studies 
Regarding hormonal studies, Posadas and colleagues (2012) found 
no differences in oestradiol and progesterone between depressed and 
non-depressed pregnant women (Posadas et al., 2012). In the post-
partum period, Klier et al. (2007) found higher oestrogen levels in pa-
tients compared to controls on the third but not the first day after 
delivery, and no group differences in progesterone levels on either day 
(Klier et al., 2007). Saleh and colleagues (2013) reported differences 
between women with PPD and controls regarding oestradiol levels one 
week after birth, with the former presenting a lower concentration than 
the latter (Saleh et al., 2013). Also examining women with vs. without 
PPD one week after birth, Chatzicharalampous and colleagues (2011) 
found no differences regarding oestradiol, progesterone, and testos-
terone (Chatzicharalampous et al., 2011). Meta-analysis conducted with 
data within the first week postpartum revealed no differences in 
oestradiol between cases and controls (k = 2; g =−0.21, 95 %CI [−0.92, 
0.50]; Z = 0.57, p = .57; I2 = 78%). A study by Harris et al. (1989) 
conducted 6–8 weeks after birth revealed that oestradiol and proges-
terone did not differ between depressed and non-depressed women 
(Harris et al., 1989). In a second study, Harris et al. (1996) examined 
progesterone at 1, 5 and 35 days after delivery and found no differences 
between women with PPD and controls (Harris et al., 1996). 
3.4. Perimenopausal depressive disorder 
Five studies evaluated perimenopausal depressive disorder and HPO- 
related parameters (see Table 4). The average score from the quality 
assessments was 4 (Karaoulanis et al., 2014; Flores-Ramos et al., 2014; 
Schmidt et al., 2002; Hui et al., 2016; Gordon et al., 2016). 
3.4.1. Follicle-stimulating hormone 
Three studies examined FSH (Karaoulanis et al., 2014; Flores-Ramos 
et al., 2014; Schmidt et al., 2002). Meta-analysis demonstrated compa-
rable levels between cases and controls (k = 2; g = 0.22, 95 %CI [−0.13, 
0.56]; Z = 1.24, p = .22; I2 = 0%). 
3.4.2. Luteinising hormone 
Three studies examined LH (Karaoulanis et al., 2014; Flores-Ramos 
et al., 2014; Schmidt et al., 2002). There were no significant differ-
ences between patients and controls (k = 2; g = 0.18, 95 %CI [−0.25, 
0.61]; Z = 0.81, p = .42; I2 = 0%). 
3.4.3. Oestradiol 
Regarding oestradiol, Flores-Ramos et al. (2014), Schmidt et al. 
(2002), Hui et al. (2016) and Karaoulanis et al. (2014) did not report 
significant differences between depressed and non-depressed perimen-
opausal women examined at one time point. Gordon et al. (2016) 
examined perimenopausal fluctuations in oestradiol over four weeks 
and detected no significant differences across time between individuals 
with perimenopausal depressive disorder and controls (Gordon et al., 
2016). Meta-analysis revealed similar oestradiol levels in perimeno-
pausal women with and without depressive disorders (k = 3; g = −0.13, 
95 %CI [−0.45, 0.20]; Z = 0.77, p = .44; I2 = 0%). 
Fig. 5. Forest plot of studies comparing progesterone in the luteal phase between women with premenstrual dysphoric disorder (PMDD) and healthy controls; 
negative effect sizes indicate that women with PMDD had lower progesterone levels than controls. 
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3.4.4. Progesterone 
The only study examining progesterone found no significant differ-
ences between patients and controls (Flores-Ramos et al., 2014). 
3.4.5. Testosterone 
Two studies examined testosterone (Flores-Ramos et al., 2014; 
Schmidt et al., 2002). Meta-analysis found no differences between pa-
tients and controls (k = 2; g = −0.17, 95 %CI [−0.56, 0.21]; Z = 0.88, p 
= .38; I2 = 0%). 
3.5. Depressive disorders unrelated to reproductive transition phases 
3.5.1. Genetic studies 
Seventeen studies investigated HPO markers in women with 
depressive disorders unrelated to reproductive transition phases and 
healthy controls. The average quality score of the hormonal studies was 
3.4 (see Table 5). 
3.5.2. Hormonal studies 
Four genetic studies examined polymorphisms within ESR1 and 
ESR2 (Tsai et al., 2003; Zhang et al., 2017; Ryan et al., 2011; Tiemeier 
et al., 2005). Tsai et al. found a significant difference in the genotype and 
allele frequencies of the ESR1 PvuII but not of the XbaI polymorphism 
between depressed Chinese women and healthy controls (Tsai et al., 
2003). By contrast, Tiemeier et al. found no significant difference in a 
related haplotype between Caucasian depressed women and controls 
(Tiemeier et al., 2005). Zhang et al. reported a statistically significant 
difference in the genotype and allele distributions of an ESR2 SNP 
(rs1256049) between Chinese women with major depressive disorder 
and healthy controls (Zhang et al., 2017). However, a second ESR2 SNP 
(rs4986938) did not differ between depressed and non-depressed 
women. Finally, Findikli et al. reported that women with depressive 
disorders had a higher G protein-coupled oestrogen receptor 1 (GPER) 
level than controls (Findikli et al., 2017). 
3.5.2.1. Follicle-stimulating hormone. Six studies examined FSH 
(Amsterdam et al., 1981; Winokur et al., 1982; Amsterdam et al., 1983; 
Antonijevic et al., 2003; Young et al., 2000; Rajewska and Rybakowski, 
2003). Meta-analysis found comparable FSH levels between depressed 
and non-depressed women (k = 2; g =−1.62, 95 %CI [−3.37, 0.13]; Z =
1.82, p = .07; I2 = 92%). A subgroup analysis by menopausal status did 
not alter the null-finding. 
3.5.2.2. Luteinising hormone. Only one out of five studies identified a 
difference in LH between depressed and non-depressed women, with 
depressed women demonstrating significantly lower levels than controls 
(Amsterdam et al., 1981; Winokur et al., 1982; Amsterdam et al., 1983; 
Antonijevic et al., 2003; Young et al., 2000). These studies could not be 
meta-analysed due to a lack of available data. 
3.5.2.3. Oestradiol. Seven studies examined oestradiol in women with 
and without depressive disorders (Amsterdam et al., 1981, 1983; 
Antonijevic et al., 2003; Young et al., 2000; Rajewska and Rybakowski, 
2003; Erdinçler et al., 2004; Findikli et al., 2017). Meta-analysis did not 
reveal any group differences (k = 4; g = −0.22; 95 %CI [−0.50, 0.05]; Z 
= 1.59, p = .11; I2 = 0%). A subgroup analysis by menopausal status did 
not alter the null-finding. 
3.5.2.4. Progesterone. Two studies assessed progesterone (Young et al., 
2000; Erdinçler et al., 2004). Meta-analysis found no group differences 
(k = 2; g = −0.93; 95 %CI [−1.93, 0.07]; Z = 1.83, p = .07; I2 = 85%). 
3.5.2.5. Testosterone. Six studies investigated testosterone (Amsterdam 
et al., 1981, 1983; Antonijevic et al., 2003; Young et al., 2000; Rajewska 
and Rybakowski, 2003; Erdinçler et al., 2004; Findikli et al., 2017). 
Meta-analysis revealed that depressed women presented with lower 
testosterone levels than healthy controls (k = 5; g = −0.58; 95 %CI 
[−0.93, −0.22]; Z = 3.19, p = .001; see also Fig. 6). The heterogeneity 
was significant (I2 = 72%; χ2 = 14.43, df = 4, p = .006). Subgroup 
analysis indicated that studies standardizing sampling regarding time of 
day were more likely to find lower testosterone in patients versus con-
trols (k = 5; g = −0.58; 95 %CI [−0.93, −0.22]; χ2 = 4.20, df = 1, p =
.04). A subgroup analysis by menopausal status did not alter this finding. 
3.5.2.6. DHEA and DHEA-S. Two studies analysed DHEA (Jiang et al., 
2017; Poór et al., 2004). These concentrations did not differ between 
depressed and non-depressed women (k = 2; g = 0.00; 95 %CI [−0.37, 
0.38], Z = 0.01, p = .99; I2 = 0%). Four studies investigated DHEA-S 
(Erdinçler et al., 2004; Markianos et al., 2007; Oulis et al., 2014; 
Jiang et al., 2017). The meta-analysis revealed comparable levels be-
tween groups (k = 4; g =−0.30, 95 %CI [−0.69, 0.08]; Z = 1.55, p = .12; 
see also Fig. 7). However, there was significant heterogeneity (I2 = 71%; 
χ2 = 10.32, df = 3; p = .02). Subgroup analyses indicated that studies 
using plasma compared to saliva found lower DHEA-S in women with 
depressive disorders versus healthy controls (k = 4; g = −0.30, 95 %CI 
[−0.69, 0.08]; Z = 1.55, p = .12; χ2 = 5.57, df = 1, p = .02). A subgroup 
analysis by menopausal status did not alter this finding. 
4. Discussion 
We report three main findings: First, studies of higher methodolog-
ical quality found lower luteal oestradiol in women with PMDD. Second, 
there was little evidence for alterations in hormones of the HPO-axis in 
women with pregnancy, postpartum, or perimenopausal depressive 
disorders. Lastly, studies of higher methodological quality found that 
women with depressive disorders unrelated to reproductive transition 
phases had comparably lower testosterone and DHEA-S levels than 
healthy controls (a summary of all results can be found in Table 6). 
The first finding suggests that study quality is crucial in research on 
PMDD, a notion that was recently highlighted in an article summarising 
methodological recommendations for research devoted to menstrual 
cycle phenomena (Schmalenberger et al., 2021). The emerging role of 
oestrogen signalling in premenstrual symptom manifestation warrants 
further research into polymorphisms and DNA methylation within oes-
trogen receptor encoding genes in this population, which may underlie 
some of the observed alterations. 
The second finding is more complex. Only one study compared 
depressed and non-depressed pregnant women during pregnancy, 
reporting a null-finding. This finding is in line with early evidence 
suggesting no significant differences in plasma oestrogen levels in these 
same groups (Mehta et al., 2014). By contrast, several studies investi-
gated women with PPD, mostly with negative findings, although one 
study reported lower oestradiol in women with PPD one week after 
postpartum. Interestingly, studies assessing hormones in relation to 
postpartum dysphoria (“baby blues”) have shown higher levels of oes-
tradiol in affected women (Heidrich et al., 1994; O’Hara et al., 1991). 
This suggests that any potential hormonal contributions to mood 
symptoms in postpartum are highly time-sensitive. In addition, genetic 
studies seem to support a role for ESR1 in the aetiology of PPD, 
corroborating similar findings by others who reported four SNPs in the 
fourth and fifth introns of ESR1 to significantly associate with PPD 
(Costas et al., 2010). By contrast, the finding that women with and 
without perimenopausal depressive disorder did not differ in HPO-axis 
parameters is in line with most longitudinal studies on hormonal vari-
ability and perimenopausal depressive symptoms (Avis et al., 2001; 
Woods et al., 2008). 
The third finding is of lower testosterone and DHEA-S levels in 
women with depressive disorders compared to healthy controls. This 
finding is in line with a recent meta-analysis, which found lower 
testosterone in men with depressive disorders as compared to healthy 
R.T. Amiel Castro et al.                                                                                                                                                                                                                       
Frontiers in Neuroendocrinology 62 (2021) 100929
10
controls (Fischer et al., 2019). As with PMDD, the testosterone finding 
was dependent on standardised morning sampling. This concurs with 
endocrinological guidelines suggesting that due to natural diurnal 
variation in testosterone levels, samples should be collected in the 
morning (Bhasin et al., 2010). Similarly, DHEA-S levels were lower in 
women suffering from depressive disorders, but only in studies taking 
plasma samples. Importantly, in the same studies, the participants’ age 
was comparably higher, which might have significantly contributed to 
the observed findings. Morrison and colleagues (Morrison et al., 2001) 
examined hormonal variation and depression in women aged 35–47 and 
concluded that higher DHEA-S levels were associated with depressive 
symptoms in younger women, whereas lower levels were associated 
with depressive symptoms in older women. However, we could not 
confirm this finding in our sample. Presently, the data is inconclusive 
regarding an involvement of polymorphisms within ESR1 and ESR2 in 
depressive disorders. Considering the scarce literature on this topic, 
further investigation is needed. 
Our study is the first systematic summary of the literature on HPO 
functioning in female mood disorders. The strict inclusion criteria in 
terms of diagnosis, potential confounders, and study design enhances 
the reliability of our findings and meta-regression and subgroup analyses 
allowed us to identify methodological factors that need to be considered 
by future research. However, caution must be exercised in interpreting 
the findings regarding certain parameters (e.g., ALLO) due to the low 
numbers of available studies. Additionally, even after contacting the 
authors, it was not possible to access a number of older datasets. 
Nevertheless, these results were included in the systematic review and 
showed an almost 100% overlap with the findings of the meta-analyses. 
The risk of bias assessment identified a number of methodological 
problems. However, our quality rating was rather conservative (e.g., 
nearly all studies lost 2 out of 10 points due to a failure to report blinding 
procedures) and meta-regression/subgroup analyses enabled us to 
identify particularly relevant factors that should be considered by future 
research. Finally, it is important to highlight that although absolute 
hormonal values seemed to have a small impact on the development of 
female depressive disorders, fluctuations in sex hormones have repeat-
edly been hypothesised to alter neurochemical pathways linked to 
depression (Soares and Zitek, 2008; Bloch et al., 2000; Schmidt et al., 
1998; Willi et al., 2021). Building on empirical findings of links between 
hormonal fluctuations and depressive symptoms (Mehta et al., 2014; Lee 
et al., 2015; Guintivano et al., 2014; Schmidt et al., 2015), it seems 
possible that there is a subgroup of women who are more prone to 
display reproductive phase transition mood disorders due to an 
increased sensitivity to such variation. 
Fig. 6. Forest plot of studies comparing testosterone between women with depressive disorders unrelated to reproductive transition phases and healthy controls; 
negative effect sizes indicate that women with depressive disorders had lower testosterone levels than controls. 
Fig. 7. Forest plot of studies comparing DHEA-S between women with depressive disorders unrelated to reproductive transition phases and healthy controls; 
negative effect sizes indicate that women with depressive disorders had lower DHEA-S levels than controls. 
Table 6 
Summary of results.  
Variables ESR1 ESR2 GPER FSH LH E2 P4 ALLO T DHEA DHEA-S 
Premenstrual dysphoric disorder * Ø          
Follicular phase    – Ø Ø Ø * Ø – – 
Ovulation phase    – – Ø Ø – Ø – – 
Luteal phase    Ø Ø * Ø Ø Ø – – 
Pregnancy depressive disorder – – – – – Ø Ø – – – – 
Postpartum depressive disorder Ø Ø – – – ¥ Ø – Ø – – 
Perimenopausal depressive disorder – – – Ø Ø Ø Ø – Ø – – 
Depressive disorders unrelated to reproductive transition phases ¥ * * Ø ¥ Ø Ø – * Ø * 
Note: * findings support a relationship between the gene/hormone and the specific mood disorder; Ø findings are non-supportive of a relationship between the gene/ 
hormone and the specific mood disorder; ¥ findings are unclear; ESR1 = gene encoding the oestrogen receptor alpha, ESR2 = gene encoding the oestrogen receptor 
beta, FSH = follicle-stimulating hormone, GPER = G protein-coupled oestrogen receptor 1, LH = luteinising hormone, E2 = oestradiol , P4 = progesterone, T =
testosterone, ALLO = allopregnanolone, DHEA = dehydroepiandrosterone, DHEA-S = dehydroepiandrosterone sulfate. 
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5. Conclusions 
In sum, we believe it is important for PMDD researchers to continue 
to adhere to highly standardised sampling schedules, and in so doing to 
assess how hormonal fluctuations contribute to symptoms across the 
menstrual cycle. In pregnancy, postpartum and perimenopausal 
depression, the magnitude of hormonal increases and decreases may 
render it more difficult to unravel the role of sex hormones in depressive 
episodes. Large-scale longitudinal studies will be crucial to help to 
detect windows of vulnerability. Finally, future studies in depressive 
disorders unrelated to reproductive transition phases should attempt to 
establish whether low testosterone/DHEA-S are antecedents or conse-
quences of depressive symptoms. A better understanding of female 
biological changes during different reproductive phases may contribute 
to effective treatment options and reduce disease burden. 
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Wang, M., Seippel, L., Purdy, R.H., Bãckström, T., 1996. Relationship between symptom 
severity and steroid variation in women with premenstrual syndrome: study on 
serum pregnenolone, pregnenolone sulfate, 5 alpha-pregnane-3, 20-dione and 3 
alpha-hydroxy-5 alpha-pregnan-20-one. J. Clin. Endocrinol. Metab. 81, 1076–1082. 
https://doi.org/10.1210/jcem.81.3.8772579. 
WHO, 1992. The ICD-10 Classification of Mental and Behavioural Disorders - Clinical 
Descriptions and Diagnostic Guidelines. World Health Organization, Geneva.  
Willi, J., Süss, H., Grub, J., Ehlert, U., 2021. Biopsychosocial predictors of depressive 
symptoms in the perimenopause-findings from the Swiss Perimenopause Study. 
Menopause 28, 247–254. https://doi.org/10.1097/GME.0000000000001704. 
Winokur, A., Amsterdam, J., Caroff, S., Snyder, P.J., Brunswick, D., 1982. Variability of 
hormonal responses to a series of neuroendocrine challenges in depressed patients. 
Am. J. Psychiatry 139, 39–44. https://doi.org/10.1176/ajp.139.1.39. 
Woods, N.F., Smith-DiJulio, K., Percival, D.B., Tao, E.Y., Mariella, A., Mitchell, E.S., 
2008. Depressed mood during the menopausal transition and early postmenopause: 
observations from the Seattle Midlife Women’s Health Study. Menopause 15, 
223–232. https://doi.org/10.1097/gme.0b013e3181450fc2. 
Yen, J.-Y., Wang, P.-W., Su, C.-H., Liu, T.-L., Long, C.-Y., Ko, C.-H., 2018. Estrogen levels, 
emotion regulation, and emotional symptoms of women with premenstrual 
dysphoric disorder: The moderating effect of estrogen receptor 1α polymorphism. 
Prog. Neuro-Psychopharmacol. Biol. Psychiatry 82, 216–223. https://doi.org/ 
10.1016/j.pnpbp.2017.11.013. 
Yen, J.-Y., Lin, H.-C., Lin, P.-C., Liu, T.-L., Long, C.-Y., Ko, C.-H., 2019. Early-and Late- 
Luteal-Phase Estrogen and Progesterone Levels of Women with Premenstrual 
Dysphoric Disorder. Int. J. Environ. Res. Public Health 16, 4352. https://doi.org/ 
10.3390/ijerph16224352. 
Young, E.A., Midgley, A.R., Carlson, N.E., Brown, M.B., 2000. Alteration in the 
hypothalamic-pituitary-ovarian axis in depressed women. Arch. Gen. Psychiatry 57, 
1157–1162. https://doi.org/10.1001/archpsyc.57.12.1157. 
Zhang, J., Chen, L., Ma, J., Qiao, Z., Zhao, M., Qi, D., Zhao, Y., Ban, B., Zhu, X., He, J., 
2017. Interaction of estrogen receptor β and negative life events in susceptibility to 
major depressive disorder in a Chinese Han female population. J. Affect. Disord. 208, 
628–633. https://doi.org/10.1016/j.jad.2016.08.083. 
R.T. Amiel Castro et al.                                                                                                                                                                                                                       
